Novartis books multimillion-dollar sales of Genmab-developed drug in Q1
Novartis’s sales of Kesimpta, a sclerosis drug developed by Genmab, are up by 290 percent in the first quarter of 2022 compared to Q1 2021.
by christian bundgaard, translated by daniel pedersen
Swiss Novartis has lit a fire under its sales of Genmab-developed multiple sclerosis drug Kesimpta, evidenced by Novartis’s financial report for the first quarter of the year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novartis increases sales of Genmab-developed sclerosis drug
For subscribers
Genmab raises 2022 sales outlook to top USD 1.6bn
For subscribers
.jpg&w=384&q=75)
